NASDAQ:FTRE - Nasdaq - US34965K1079 - Common Stock - Currency: USD
NASDAQ:FTRE (5/12/2025, 2:48:10 PM)
5.05
-1.1 (-17.89%)
The current stock price of FTRE is 5.05 USD. In the past month the price increased by 18.04%. In the past year, price decreased by -81.38%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 19.66 | 162.56B | ||
DHR | DANAHER CORP | 26.78 | 142.78B | ||
A | AGILENT TECHNOLOGIES INC | 21.71 | 32.86B | ||
IQV | IQVIA HOLDINGS INC | 13.77 | 27.43B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 28.9 | 24.37B | ||
WAT | WATERS CORP | 30.83 | 21.85B | ||
WST | WEST PHARMACEUTICAL SERVICES | 32.74 | 15.62B | ||
ILMN | ILLUMINA INC | 24.15 | 12.73B | ||
RVTY | REVVITY INC | 19.89 | 11.78B | ||
ICLR | ICON PLC | 10.31 | 11.68B | ||
TEM | TEMPUS AI INC | N/A | 10.96B | ||
QGEN | QIAGEN N.V. | 18.49 | 9.19B |
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina. The company went IPO on 2023-06-16. The firm is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The firm offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The firm manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The firm has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
FORTREA HOLDINGS INC
8 Moore Drive
Durham NORTH CAROLINA US
Employees: 16000
Phone: 18774950816
The current stock price of FTRE is 5.05 USD. The price decreased by -17.89% in the last trading session.
The exchange symbol of FORTREA HOLDINGS INC is FTRE and it is listed on the Nasdaq exchange.
FTRE stock is listed on the Nasdaq exchange.
16 analysts have analysed FTRE and the average price target is 7.75 USD. This implies a price increase of 53.5% is expected in the next year compared to the current price of 5.05. Check the FORTREA HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
FORTREA HOLDINGS INC (FTRE) has a market capitalization of 457.23M USD. This makes FTRE a Small Cap stock.
FORTREA HOLDINGS INC (FTRE) currently has 16000 employees.
FORTREA HOLDINGS INC (FTRE) has a support level at 5.68 and a resistance level at 6.27. Check the full technical report for a detailed analysis of FTRE support and resistance levels.
The Revenue of FORTREA HOLDINGS INC (FTRE) is expected to decline by -8.16% in the next year. Check the estimates tab for more information on the FTRE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
FTRE does not pay a dividend.
FORTREA HOLDINGS INC (FTRE) will report earnings on 2025-05-12, before the market open.
The PE ratio for FORTREA HOLDINGS INC (FTRE) is 14.85. This is based on the reported non-GAAP earnings per share of 0.34 and the current share price of 5.05 USD. Check the full fundamental report for a full analysis of the valuation metrics for FTRE.
The outstanding short interest for FORTREA HOLDINGS INC (FTRE) is 6.76% of its float. Check the ownership tab for more information on the FTRE short interest.
ChartMill assigns a technical rating of 1 / 10 to FTRE. When comparing the yearly performance of all stocks, FTRE is a bad performer in the overall market: 98.18% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to FTRE. FTRE has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months FTRE reported a non-GAAP Earnings per Share(EPS) of 0.34. The EPS decreased by -9582.54% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -9.18% | ||
ROE | -24.11% | ||
Debt/Equity | 0.77 |
ChartMill assigns a Buy % Consensus number of 51% to FTRE. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 33.53% and a revenue growth -8.16% for FTRE